Merz Pharmaceuticals recently announced that Xeomin is now commercially available in the U.S. Similar to BOTOX and Dysport, Xeomin is a botulinum toxin type A which is injection to cease muscle spasms from the nerve. Recently FDA-approved, the Botox alternative Xeomin, is used to treat adults with cervical dystonia (CD) or blepharospasm. What sets Xeomin apart from other botulinum toxins is the lack of accessory proteins within the solution.
"We are excited that Xeomin is now available in the U.S.," said Jack Britts, President and CEO of Merz Pharmaceuticals. "Merz is committed to patients having access to the product by providing a variety of service offerings and financial assistance programs for patients. We are pleased with the initial response from healthcare professionals and patients and we believe Xeomin will make a difference in the lives of CD and blepharospasm patients who receive the product."
Merz has developed a product support system that will offer a single point of contact for both providers and patients. This system will help providers with ordering and product information. For eligible patients, Merz will offer a drug co-pay assistance program to help with out-of-pocket costs.
While Xeomin is not FDA approved for cosmetic use, physicians will be able to use it off-label, similar to how BOTOX was initially brought into the market.